On April 21, three Madison, Connecticut residents are running to defy cancer as a member of the Dana-Farber Marathon ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer ...

Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr.

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr.